Lobbying World

By The Hill Staff - 07/31/12 07:10 PM ET

• W. Jackson “Jack” Coleman has joined Arent Fox as a counsel to the firm’s government-relations and energy practices. He will mostly concentrate on clients in the oil and gas industry, according to a statement from the firm. Most recently, Coleman worked as the managing partner at EnergyNorthAmerica, a consulting firm. He has also worked as a counsel for the House Committee on Natural Resources and a senior attorney at the Department of the Interior, among other posts in the federal government.

• John Thorne has become a partner at Kellogg, Huber, Hansen, Todd, Evans & Figel. He plans to work on issues regarding mergers, DOJ and FCC matters and intellectual property at the firm. Thorne most recently served as Verizon’s deputy general counsel, focusing on antitrust issues. Thorne also worked at Ameritech Corp. (now AT&T Teleholdings) and Kirkland & Ellis.

• Bruce Fried is a new managing partner in SNR Denton’s Washington office. He will continue his work in the firm’s healthcare practice. His clients include physician organizations, hospital groups, consumer organizations, healthcare information technology companies and pharmaceutical and biotech companies, among others. He served as part of then-President-elect Bill Clinton’s transition team for health policy.

• William “Bud” Barrow II, Thomas Burke, Carolyn Caldwell, Joanne Carrocino, Vickie Diamond, Bea Grause and Jim Skogsbergh have been elected to the American Hospital Association’s board of trustees for three-year terms beginning on Jan. 1, 2013. The board also appointed Eugene Woods to fill a one-year vacancy, making him eligible for a full term in 2014. The new board members hold executive and prominent positions at medical facilities around the country.

• Charles A. Weiss has been hired by Holland & Knight as a partner and the head of the firm’s New York Intellectual Property Group. He has “litigated patent, trade secret, license and false advertising cases involving matters such as the expression of recombinant proteins, controlled-release pharmaceuticals, medical diagnostic agents, endocrine and hormone products, nutritional supplements, food chemistry and processing, high-caustic detergents, pipe liners and tube fittings,” according to a statement.